In the processes of treating most cancers, one of the key pieces of information is the appearance of the tumor under the microscope using a technique called light microscopy. In lung cancer, for example, the appearance of the tumor determines both which chemotherapies are safe and which chemotherapies are effective. In addition, tumor appearance also suggests which patients should be tested for mutations that can be targeted by some of the most effective and safest drugs on the market.
Chapel Hill, NC – Norman E. “Ned” Sharpless, MD, professor of medicine and genetics and Associate Director for Translational Research at UNC Lineberger Comprehensive Cancer Center has been appointed the Wellcome Distinguished Professor in Cancer Research. The professorship was established by the School of Medicine in 1988 with gifts from the Burroughs Wellcome Fund and the William A. Smith Trust of Wadesboro, NC. The gifts were supplemented by the state of North Carolina the Distinguished Professors Endowment Trust Fund to create the endowed professorship.
The finding presents a possible explanation for why so many cancers possess not just genomic instability, but also more or less than the usual 46 DNA-containing chromosomes.
Chapel Hill, NC – Susan G. Komen for the Cure® has awarded a grant of almost $900,000 to Lisa A. Carey, MD, and Gary Johnson, PhD, to research clinical applications for the first broad-based test for protein kinase activation and response to inhibitory drugs in HER2-positive breast cancer.
Chapel Hill, NC – Multiple myeloma is a form of cancer where the plasma cells in the bone marrow grow out of control, causing damage to bones as well as predisposing patients to anemia, infection and kidney failure. A medical procedure called autologous hematopoietic stem cell transplantation, commonly known as a stem cell transplant, is frequently an important treatment option for many patients.
Chapel Hill - Cancer therapies targeting specific molecular subtypes of the disease allow physicians to tailor treatment to a patient’s individual molecular profile. But scientists are finding that in many types of cancer the molecular subtypes are more varied than previously thought and contain further genetic alterations that can affect a patient’s response to therapy.
Chapel Hill, NC –A medical procedure called allogeneic hematopoietic cell transplantation, commonly known as a bone marrow or stem cell transplant, is the only known curative option for many patients with life-threatening blood-borne cancers such as leukemia and lymphoma.
Jason Lieb likes to mix it up. A triathlete, he enjoys running, swimming and cycling. In his lab, he works in several model systems: yeast, round worms (C. elegans), fruit flies (Drosophila melanogaster) and human cell lines.
Idoia Garcia, PhD, a postdoctoral fellow in the lab of Timothy Gershon, MD, PhD, has been awarded a Department of Defense Visionary Postdoctoral Fellowship Award. The peer-reviewed award is intended to support exceptionally talented recent medical or other doctoral graduates in their pursuit of cutting-edge, innovative, high-risk/high-impact cancer research during their postdoctoral fellowship.
Channing Der, PhD, Sarah Graham Kenan Professor of Pharmacology, received a two-year $200,000 American Association for Cancer Research Innovative grant from the Pancreatic Cancer Action Network. His grant will fund research on the mechanism of ERK inhibition resistance and ERK-dependent pancreatic cancer.
American and Spanish researchers report potential ways for doctors to improve the treatment of hormone receptor-positive breast cancer even if they lack access to costly multi-gene tests.
Which treatment for prostate cancer is most effective? Will a specific combination of cancer drugs increase patient survival for colon cancer? As the pace of scientific discovery continues to accelerate, patients and their providers face more choices and decisions about how to address their health care needs, and information that can help inform their decisions is often hard to find.
Embryonic stem cells are primed to kill themselves if damage to their DNA makes them a threat to the developing embryo. UNC researchers reveal how they do it.
Dr. Joseph DeSimone, PhD, Chancellor's Eminent Professor of Chemistry at the University of North Carolina at Chapel Hill, has been elected into the National Academy of Sciences, one of the highest honors that a U.S. scientist or engineer can receive.
Matthew Milowsky, MD, was recently quoted in the online journal Health News Digest on new therapies for bladder cancer.
Joseph S. Pagano, MD, has been awarded the fifth annual Hyman L. Battle Distinguished Cancer Research Award in recognition of his accomplishments in cancer research. Dr. Pagano is the director emeritus of UNC Lineberger Comprehensive Cancer Center.
Current nanomedicine research has focused on the delivery of established and novel therapeutics. But a UNC team is taking a different approach.
UNC Lineberger’s 36th annual scientific symposium drew large crowds, with over 450 participants.
UNC’s Seth Noar examines intersection of technology and health
Paul Armistead, MD, PhD, has received a grant of more than $396,000 from the National Heart, Lung and Blood Institute (part of the National Institutes of Health) to study leukemia stem cell-associated minor histocompatibility antigens.
UNC junior Molly DeCristo attended her first international scientific meeting, but not just as a participant. The American Association for Cancer Research (AACR) honored her poster with a rosette, judging it as “highly rated,” among the top 2.5 percent of those submitted.
A Wayne County woman doesn’t let cancer, its treatment or its recurrence get in the way of her plans to attend her oldest granddaughter’s high school graduation or her own 45th high school reunion.
Chapel Hill - A treatment for localized prostate cancer known as Intensity Modulated Radiation Therapy (IMRT) is better than conventional conformal radiation therapy (CRT) for reducing certain side effects and preventing cancer recurrence, according to a study published in the April 18, 2012 issue of the Journal of the American Medical Association. In 2012, approximately 241,740 American men will be diagnosed with prostate cancer.